Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

A signature of circulating inflammatory proteins and development of end-stage renal disease in diabetes.

Niewczas MA, Pavkov ME, Skupien J, Smiles A, Md Dom ZI, Wilson JM, Park J, Nair V, Schlafly A, Saulnier PJ, Satake E, Simeone CA, Shah H, Qiu C, Looker HC, Fiorina P, Ware CF, Sun JK, Doria A, Kretzler M, Susztak K, Duffin KL, Nelson RG, Krolewski AS.

Nat Med. 2019 May;25(5):805-813. doi: 10.1038/s41591-019-0415-5. Epub 2019 Apr 22.

2.

High levels of circulating TNFR1 increase the risk of all-cause mortality and progression of renal disease in type 2 diabetic nephropathy.

Fernández-Juárez G, Villacorta Perez J, Luño Fernández JL, Martinez-Martinez E, Cachofeiro V, Barrio Lucia V, Tato Ribera AM, Mendez Abreu A, Cordon A, Oliva Dominguez JA, Praga Terente M.

Nephrology (Carlton). 2017 May;22(5):354-360. doi: 10.1111/nep.12781.

PMID:
27003829
3.

Type 2 diabetes in patients with end-stage renal disease is not associated with further increased serum inflammatory parameters.

Bodlaj G, Berg J, Pichler R, Sailer T, Biesenbach G.

J Nephrol. 2004 Jan-Feb;17(1):112-7.

PMID:
15151267
4.

Improved clinical trial enrollment criterion to identify patients with diabetes at risk of end-stage renal disease.

Yamanouchi M, Skupien J, Niewczas MA, Smiles AM, Doria A, Stanton RC, Galecki AT, Duffin KL, Pullen N, Breyer MD, Bonventre JV, Warram JH, Krolewski AS.

Kidney Int. 2017 Jul;92(1):258-266. doi: 10.1016/j.kint.2017.02.010. Epub 2017 Apr 7.

5.

Added value of soluble tumor necrosis factor-α receptor 1 as a biomarker of ESRD risk in patients with type 1 diabetes.

Forsblom C, Moran J, Harjutsalo V, Loughman T, Wadén J, Tolonen N, Thorn L, Saraheimo M, Gordin D, Groop PH, Thomas MC; FinnDiane Study Group.

Diabetes Care. 2014 Aug;37(8):2334-42. doi: 10.2337/dc14-0225. Epub 2014 May 30.

PMID:
24879837
6.

Risk of ESRD and all cause mortality in type 2 diabetes according to circulating levels of FGF-23 and TNFR1.

Lee JE, Gohda T, Walker WH, Skupien J, Smiles AM, Holak RR, Jeong J, McDonnell KP, Krolewski AS, Niewczas MA.

PLoS One. 2013;8(3):e58007. doi: 10.1371/journal.pone.0058007. Epub 2013 Mar 20.

7.

Plasma high-sensitivity troponin T predicts end-stage renal disease and cardiovascular and all-cause mortality in patients with type 1 diabetes and diabetic nephropathy.

Galsgaard J, Persson F, Hansen TW, Jorsal A, Tarnow L, Parving HH, Rossing P.

Kidney Int. 2017 Nov;92(5):1242-1248. doi: 10.1016/j.kint.2017.04.018. Epub 2017 Jul 14.

PMID:
28712855
8.

Serum C-peptide concentrations poorly phenotype type 2 diabetic end-stage renal disease patients.

Covic AM, Schelling JR, Constantiner M, Iyengar SK, Sedor JR.

Kidney Int. 2000 Oct;58(4):1742-50.

9.

The early decline in renal function in patients with type 1 diabetes and proteinuria predicts the risk of end-stage renal disease.

Skupien J, Warram JH, Smiles AM, Niewczas MA, Gohda T, Pezzolesi MG, Cantarovich D, Stanton R, Krolewski AS.

Kidney Int. 2012 Sep;82(5):589-97. doi: 10.1038/ki.2012.189. Epub 2012 May 23.

10.

Association of serum concentration of TNFR1 with all-cause mortality in patients with type 2 diabetes and chronic kidney disease: follow-up of the SURDIAGENE Cohort.

Saulnier PJ, Gand E, Ragot S, Ducrocq G, Halimi JM, Hulin-Delmotte C, Llaty P, Montaigne D, Rigalleau V, Roussel R, Velho G, Sosner P, Zaoui P, Hadjadj S; SURDIAGENE Study Group.

Diabetes Care. 2014 May;37(5):1425-31. doi: 10.2337/dc13-2580. Epub 2014 Mar 12.

PMID:
24623026
11.

Plasma Adrenomedullin and Allelic Variation in the ADM Gene and Kidney Disease in People With Type 2 Diabetes.

Velho G, Ragot S, Mohammedi K, Gand E, Fraty M, Fumeron F, Saulnier PJ, Bellili-Munoz N, Bouby N, Potier L, Alhenc-Gelas F, Marre M, Hadjadj S, Roussel R.

Diabetes. 2015 Sep;64(9):3262-72. doi: 10.2337/db14-1852. Epub 2015 May 6.

12.

Sex modulates the association of fibroblast growth factor 21 with end-stage renal disease in Asian people with Type 2 diabetes: a 6.3-year prospective cohort study.

Liu JJ, Liu S, Choo RWM, Wee SL, Xu A, Lim SC.

Diabet Med. 2018 Jul;35(7):880-886. doi: 10.1111/dme.13641. Epub 2018 May 2.

PMID:
29653030
13.

Serum adiponectin predicts all-cause mortality and end stage renal disease in patients with type I diabetes and diabetic nephropathy.

Jorsal A, Tarnow L, Frystyk J, Lajer M, Flyvbjerg A, Parving HH, Vionnet N, Rossing P.

Kidney Int. 2008 Sep;74(5):649-54. doi: 10.1038/ki.2008.201. Epub 2008 May 21.

14.

Apolipoprotein E4 reduces risk of diabetic nephropathy in patients with NIDDM.

Kimura H, Suzuki Y, Gejyo F, Karasawa R, Miyazaki R, Suzuki S, Arakawa M.

Am J Kidney Dis. 1998 Apr;31(4):666-73.

PMID:
9531184
15.

End-stage renal disease attributable to diabetes mellitus.

Perneger TV, Brancati FL, Whelton PK, Klag MJ.

Ann Intern Med. 1994 Dec 15;121(12):912-8.

PMID:
7978716
16.

Plasma copeptin and renal outcomes in patients with type 2 diabetes and albuminuria.

Velho G, Bouby N, Hadjadj S, Matallah N, Mohammedi K, Fumeron F, Potier L, Bellili-Munoz N, Taveau C, Alhenc-Gelas F, Bankir L, Marre M, Roussel R.

Diabetes Care. 2013 Nov;36(11):3639-45. doi: 10.2337/dc13-0683. Epub 2013 Jul 17.

17.

Fast renal decline to end-stage renal disease: an unrecognized feature of nephropathy in diabetes.

Krolewski AS, Skupien J, Rossing P, Warram JH.

Kidney Int. 2017 Jun;91(6):1300-1311. doi: 10.1016/j.kint.2016.10.046. Epub 2017 Mar 31. Review.

18.

Uremic solutes and risk of end-stage renal disease in type 2 diabetes: metabolomic study.

Niewczas MA, Sirich TL, Mathew AV, Skupien J, Mohney RP, Warram JH, Smiles A, Huang X, Walker W, Byun J, Karoly ED, Kensicki EM, Berry GT, Bonventre JV, Pennathur S, Meyer TW, Krolewski AS.

Kidney Int. 2014 May;85(5):1214-24. doi: 10.1038/ki.2013.497. Epub 2014 Jan 15.

19.

Soluble Urokinase Plasminogen Activator Receptor and Outcomes in Patients with Diabetes on Hemodialysis.

Drechsler C, Hayek SS, Wei C, Sever S, Genser B, Krane V, Meinitzer A, März W, Wanner C, Reiser J.

Clin J Am Soc Nephrol. 2017 Aug 7;12(8):1265-1273. doi: 10.2215/CJN.10881016. Epub 2017 May 11.

20.

Association of soluble tumor necrosis factor receptors 1 and 2 with nephropathy, cardiovascular events, and total mortality in type 2 diabetes.

Carlsson AC, Östgren CJ, Nystrom FH, Länne T, Jennersjö P, Larsson A, Ärnlöv J.

Cardiovasc Diabetol. 2016 Feb 29;15:40. doi: 10.1186/s12933-016-0359-8.

Supplemental Content

Support Center